Description

HA-966 HCl, Powder

HA-966 HCl (1-Hydroxy-3-amino-pyrrolidone-2 Hydrochloride) is a research compound with unique pharmacological properties. It acts as a partial agonist at the glycine-binding site of the NMDA receptor and a glycine receptor antagonist. Glycine is a co-agonist for NMDA receptors, and NMDA receptors play a key role in synaptic plasticity, learning, memory, and neuroprotection.

Due to its modulation of the NMDA receptor complex, HA-966 has been studied for its potential neuroprotective effects and its role in modulating glutamate-driven excitotoxicity, a process that can lead to neuronal damage in conditions like stroke, epilepsy, and neurodegenerative diseases. It also demonstrates anticonvulsant properties, making it relevant in research focused on seizure activity.

Mechanism of Action:

HA-966 exerts its effects through several key mechanisms related to NMDA receptor modulation:

• Glycine Receptor Antagonism: HA-966 blocks glycine at the NMDA receptor’s glycine-binding site, which in turn modulates NMDA receptor activity. This can lead to altered synaptic transmission, influencing processes related to memory, cognition, and neuroprotection.
• Partial Agonism at Glycine Sites: HA-966 also functions as a partial agonist at the same site, giving it the unique ability to both modulate excitatory transmission and influence neuroprotection.

These properties make HA-966 of interest in neuropharmacological research, particularly regarding glutamatergic signaling, cognitive function, and neuroprotection from excitotoxic damage.

Benefits:

• Neuroprotective Potential: By modulating NMDA receptor activity and preventing excitotoxicity, HA-966 is being researched for its potential to protect neurons from damage, particularly in models of neurodegenerative diseases and acute brain injuries.
• Modulation of Cognitive Processes: Due to its influence on the NMDA receptor, HA-966 may impact learning and memory processes through its modulation of synaptic plasticity and neurotransmission.
• Anticonvulsant Properties: HA-966 has demonstrated anticonvulsant effects in preclinical studies, making it relevant in the study of seizure disorders and neuroprotection.

Clinical Research:

• Neuroprotection and NMDA Modulation: Studies, such as those by Wong et al. (1996), have explored the role of HA-966 in protecting neurons from glutamate-induced excitotoxicity by modulating NMDA receptor activity. These studies suggest that compounds like HA-966 can play a neuroprotective role in conditions such as stroke or traumatic brain injury.
• Anticonvulsant Activity: Research by Meldrum et al. (1995) indicates that HA-966 has anticonvulsant effects, highlighting its potential use in the treatment of seizure-related conditions.

Additional Effects:

• Glutamatergic Modulation: Through its interaction with the NMDA receptor, HA-966 may influence glutamatergic transmission, which is involved in many cognitive processes, including memory formation and learning.
• Potential in Neurological Research: HA-966 is being studied for its potential applications in various neurological conditions, particularly those involving dysregulation of glutamate signaling or excitotoxic damage.

For a detailed lab analysis and comprehensive product specifications, please refer to the sections below.